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Impact of availability and use of coronary interventions
on the prescription of aspirin and lipid lowering
treatment after acute coronary syndromes
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for the ENACT investigators
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Heart 2002;88:20–24
Background: It has been suggested that patients undergoing acute intervention for coronary
syndromes may not receive adequate secondary prevention.
Objective: To analyse the impact of availability and use of coronary interventions on the prescription
of secondary prevention after acute coronary syndromes.
Design: Analysis of a prospective multicentre register of patients admitted to hospital for acute coron-
ary syndromes.
Setting: A 1999 pan-European survey in 390 hospitals.
Patients: 3092 patients admitted to hospital with acute coronary syndromes (including 777 for ST
elevation myocardial infarction within 12 hours of onset).
Main outcome measures: Rates of prescription of aspirin and lipid lowering agents.
Results: Performance of coronary angiography and percutaneous coronary interventions (PCI) during
the hospital stay were independent predictors of prescription of aspirin at discharge (odds ratio (OR)
1.29 and 1.89, p = 0.053 and p < 0.0001, respectively). Lipid lowering agents were prescribed
more often on discharge in patients admitted to hospitals with catheterisation laboratories than without
(for infarction with ST elevation, 45% v 40% (NS); for other acute coronary syndromes, 46% v 36%;
p < 0.05). Prescription rates were higher among patients undergoing coronary angiography or PCI
than in those treated conservatively (for infarction with ST elevation, 49%, 53%, and 39%, p < 0.05;
for other acute coronary syndromes, 50%, 54%, and 34%, p < 0.05). Logistic regression analysis
showed that PCI was an independent predictor of prescription of lipid lowering agents at discharge
(OR 1.48, p < 0.0002).
Conclusions: Contrary to expectations, invasive procedures for acute coronary syndromes are associ-
ated with higher rates of prescription of pharmacological secondary prevention.
There is solid evidence that secondary prevention measuresare effective in reducing morbidity and mortality afteracute coronary syndromes. For example, the antiplatelet
trialist collaboration showed that prescription of aspirin after
myocardial infarction results in a reduction in cardiovascular
events by approximately 25%.1 Because few patients have con-
traindications to aspirin treatment, prescription of this drug is
appropriate for nearly all survivors of myocardial infarction.
Likewise, several trials have shown the benefit of aspirin after
unstable angina.2 3
Lipid lowering treatment has been found to be effective in
reducing morbidity and mortality after acute coronary
syndromes in patients with raised or even “average”
cholesterol concentrations.4 5 Recently, observational data
have suggested remarkable short term benefits among survi-
vors of acute coronary syndromes discharged on statin
treatment as opposed to patients not receiving statins,6 7 and
lipid lowering treatment appears to be particularly beneficial
after an unstable angina event.8 A recent trial has suggested a
major benefit of early introduction of statins following acute
coronary syndromes.9
β Blockers are also effective at reducing mortality and rein-
farction in survivors of acute myocardial infarction,10 and
angiotensin converting enzyme (ACE) inhibitors have been
shown to be effective in all patients with clinical or objective
evidence of heart failure or left ventricular dysfunction.10 More
recently, the HOPE (heart outcomes prevention evaluation)
trial showed that the benefit of ACE inhibitors might be
expanded to larger groups of patients.11
Thus effective treatments are currently available for
secondary prevention in patients admitted to hospital with
acute coronary syndromes. However, both US and European
registries suggest that there is a general underperformance in
implementing secondary prevention,12–14 and recent data show
only modest improvement in the rates of prescription of effec-
tive agents, with substantial numbers of patients not receiving
treatment.14 15
While the underuse of secondary prevention measures is
clearly documented, the reasons for such underperformance
are still unclear. There is concern that part of this failure to
implement secondary prevention effectively is because of an
excessive focus on the early management of acute coronary
syndromes, and specifically coronary interventions (for exam-
ple, coronary angiography and percutaneous coronary inter-
ventions (PCI)).16 In this study we analyse the impact of the
availability and use of coronary interventions on the prescrip-
tion of pharmacological secondary prevention measures.
METHODS
The ENACT (European network for acute coronary treatment)
registry collected prospectively pan-European information on
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relative frequency, diagnosis, and management of patients
with acute coronary syndromes. Data were collected in 1999
from 3092 patients from 390 sites in 29 European countries.
The methods and main results of the ENACT survey were
published earlier.17 18 The data from ENACT were used to com-
pare the rates of prescription of aspirin or lipid lowering
agents at discharge according to the type of hospital (teaching
v community, with and without a catheterisation laboratory),
as well as the invasive procedures performed during the index
hospital stay (coronary angiography, PCI, or neither). Similar
analyses were done for in-hospital prescription of β blockers
and ACE inhibitors. Data were not censored for death: in
patients who died in hospital, the last treatment used was
recorded and used as “discharge” treatment in the analysis. A
hospital with a catheterisation laboratory was defined as one
where the investigator undertook angiography on site. The
data were analysed separately for the 770 patients with myo-
cardial infarction associated with ST segment elevation within
12 hours of the onset of symptoms, and the 2322 patients with
all other acute coronary syndromes.
Statistical methods
Quantitative variables are expressed as mean (SD). When
included in a logistic model, they are divided into subgroups
following the results of univariate analysis.
In a univariate analysis we used the unpaired Student’s t
test for quantitative variables and the χ2 test for qualitative
variables. Univariate analysis included 18 variables: two were
related to the type of hospital (teaching or community hospi-
tal, with or without catheterisation laboratory); six were
related to the patients’ baseline characteristics (age, sex,
smoking, hypertension, dyslipidaemia, diabetes); six were
related to patient management (thrombolysis, any reper-
fusion, coronary angiography, percutaneous transluminal cor-
onary angioplasty, stenting, coronary artery bypass graft sur-
gery); and four were related to outcome during the hospital
admission (peak creatine kinase, heart failure, final diagnosis
cardiac/non-cardiac, and final diagnosis ST elevation during
the first 12 hours/other acute coronary syndromes).
Variables for which the probability value was p < 0.10 were
entered in a logistic model without interactions and were
selected by a backwards procedure with a significance level of
p = 0.05. Adjusted odds ratios were derived from the
coefficients of the final multivariate logistic model.
All analyses were performed using the SAS statistical soft-
ware (SAS Institute, Cary, North Carolina, USA; release 6.11),
and estimation of the coefficients of the logistic model used
the logistic procedure.
RESULTS
The baseline characteristics of the patients are described in
table 1 as a function of the type of hospital. When patients
were examined on the basis of use of procedures (table 2),
those undergoing invasive procedures were younger, less often
female, more likely to have had previous revascularisation,
and more likely to have received lipid lowering treatment
before admission. They were also more often smokers.
Prescription of aspirin at discharge
Prescription of aspirin at discharge was common across all
patient subsets (table 3). There was no difference in rates of
prescription of aspirin based upon the type of hospital setting
(teaching v community), and rates were similar in hospitals
with and without catheterisation laboratories. When rates of
prescription were examined as a function of the use of invasive
procedures (angiography and/or PCI), there was a consistent
trend towards a higher rate of aspirin prescription among
patients treated invasively (for infarction with ST elevation,
85% v 79%; for other acute coronary syndromes, 83% v 76%;
NS for both comparisons). Multivariate analysis using logistic
regression analysis showed that performance of PCI or coron-
ary angiography during hospital stay were among the
Table 1 Baseline characteristics of the patients as a function of hospital type
Characteristic

















Age (years) 61.6 63.2 61.7 63.2 64.5 65.7 63.8 66.0
Female sex (%) 23 24 21 26 31 32 31 32
Previous angina (%) 36 28 32 31 58 50 56 53
Previous MI/heart failure (%) 21 17 22 17 34 32 33 33
Previous revascularisation (%) 8 5 10 4 20 15 21 15
Hypertension (%) 42 35 38 39 52 48 52 47
Diabetes (%) 17 12 17 13 24 22 23 22
Lipid lowering treatment (%) 23 19 21 21 31 25 31 26
Smoking (%) 51 49 51 49 39 35 39 36
Cath lab+/−, hospitals with/without catheter laboratories; Community, community hospital; MI, myocardial infarction.
Table 2 Baseline characteristics as a function of performance of invasive procedures
Characteristic













Age (years) 59.1* 59.3* 64.4 62.2* 62.6* 66.9
Female sex (%) 19* 19* 27 28 29 34
Previous angina (%) 35 36 30 60* 60* 51
Previous MI/heart failure (%) 21 18 18 31 30 34
Previous revascularisation (%) 11* 10* 4 22* 23* 15
Hypertension (%) 41 43 38 52* 51 47
Diabetes (%) 11 14 15 23 21 23
Lipid lowering treatment (%) 28* 27* 17 36* 39* 22
Smoking (%) 55 57* 48 42* 39 35
*p<0.05 v neither procedure.
Angio, coronary angiography; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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independent predictors of the prescription of aspirin at
discharge from the hospital (odds ratio (OR) 1.89 and 1.29,
respectively) (table 4).
Prescription of lipid lowering agents
On discharge, only a minority of patients were prescribed a
lipid lowering agent. There were higher prescription rates in
teaching hospitals than in community hospitals (for infarc-
tion with ST elevation, 46% v 41% (NS); for other acute coron-
ary syndromes, 44% v 37%; p < 0.05). Likewise, there were
more frequent prescriptions in hospitals with catheterisation
laboratories than in those without (for infarction with ST
elevation, 45% v 40% (NS); for other acute coronary
syndromes, 46% v 36%; p < 0.05) (fig 1). Patients undergoing
angiography or PCI were more often prescribed lipid lowering
agents than patients who were managed conservatively (fig 2)
(for infarction with ST elevation, 49%, 53%, and 39%,
p < 0.05; for other acute coronary syndromes, 50%, 54%, and
34%, p < 0.05).
Multivariate analysis showed that, apart from being
dyslipidaemic, undergoing PCI was an independent predictor
of prescription of lipid lowering agents at discharge (OR 1.48,
p < 0.0002) (table 5).
Prescription of β blockers and ACE inhibitors
β Blockers were prescribed to more than 60% of patients in the
registry, with a higher rate of prescription in patients admitted
for acute coronary syndromes other than ST elevation infarc-
tion to hospitals equipped with catheterisation laboratories
(68% v 63% in hospitals without catheterisation laboratories,
p < 0.05) (table 6). Likewise, when the use of these agents
was analysed on the basis of procedures performed, there was
more frequent use of β blockers in patients who underwent
angiography or PCI for acute coronary syndromes than in
patients who did not (77% and 78% v 57%, p < 0.05).
ACE inhibitors were prescribed in more than half the
patients with ST elevation infarction, with similar rates across
hospital types and patient subsets (table 6). In patients with
other forms of acute coronary syndromes, prescription was
less frequent—generally below 50% and quite comparable
Table 3 Prescription of aspirin at time of discharge
Variable
Aspirin prescribed
ST elevation MI <12 h
Other acute coronary
syndromes
According to hospital type
Teaching hospital 83 82
Community hospital 81 77
According to availability of catheterisation facilities
With catheter lab 79 78
Without catheter lab 83 80
According to performance of procedures
Underwent angiography 85 83
Underwent PCI 86 88
Underwent neither 79 76
Values are %. PCI, percutaneous coronary intervention.
Table 4 Logistic regression analysis off predictors of aspirin at time of discharge
Variable Wald χ2 OR 95% CI p Value
Cardiac diagnosis 45.9 3.04 2.20 to 4.20 0.0001
Heart failure 35.2 1.96 1.57 to 2.44 0.0001
PCI 14.8 1.89 1.37 to 2.61 0.0001
Teaching hospital 8.7 1.35 1.11 to 1.65 0.0032
Male sex 7.2 1.32 1.08 to 1.61 0.007
Coronary angiography 3.7 1.29 0.99 to 1.66 0.053
CI, confidence interval; OR, odds ratio; PCI, percutaneous coronary intervention.
Figure 1 Prescription of lipid lowering treatment at discharge as a
function of hospital type. Cath lab+/−, hospitals with or without a
catheterisation laboratory; STE-MI, ST elevation myocardial
infarction; ACS, acute coronary syndromes. *p<0.05 versus
















































Figure 2 Prescription of lipid lowering treatment at discharge as a
function of invasive procedures performed during the index hospital
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across groups—although fewer patients received ACE inhibi-
tors in hospitals with catheterisation facilities than in those
without (43% v 47%, p < 0.05).
For both β blockers and ACE inhibitors, prescription is likely
to be affected by important variables—such as measures of left
ventricular function—which were not collected in the registry.
In addition, the data collected represent in-hospital use but
not prescription on discharge. Thus no sound adjustment for
baseline characteristics was possible and logistic regression
analysis of prescription rates was not performed.
DISCUSSION
There is a strong rationale for the widespread prescription of
pharmacological secondary prevention using aspirin, lipid
lowering agents, and β blockers after acute coronary
syndromes, and growing evidence of the benefit of ACE
inhibitors. The disappointingly low rates of prescription of
these agents observed in large registries has several hypotheti-
cal explanations, such as lack of belief by physicians in their
effectiveness, lag in the diffusion of guidelines, excessive
attention focused on acute care,16 and so on. Understanding
the factors resulting in such underperformance is critical for
improving patient care and outcomes.
We addressed the concern that the current increasing use of
interventional procedures may detract from paying proper
attention to secondary prevention. The present data, gathered
from a recent international patient cohort—similar in size and
methods to the EUROASPIRE registries—suggest otherwise:
in fact, invasive procedures for acute coronary syndromes are
associated with a modest but significant increase in the rates
of prescription of pharmacological secondary prevention, both
in patients with ST elevation infarction and in those with
other acute coronary syndromes. In this registry, multivariate
analysis adjusting for patients and hospital characteristics
showed that performance of PCI was an independent predic-
tor of the prescription of aspirin or lipid lowering agents. Our
results are in agreement with the recent findings by Fonarow
and colleagues that in patients with acute myocardial infarc-
tion, performance of cardiac catheterisation or PCI during the
hospital stay was independently associated with the prescrip-
tion of lipid lowering agents.12 It is important to stress that, at
the time of the survey (in 1999), there was less evidence of the
benefit of introducing lipid lowering treatment immediately
after an acute coronary syndrome,6–8 and this issue may have
influenced the prescription of lipid lowering agents.
Limitations
There are certain limitations to this analysis.
Firstly, participation in the registry was voluntary; therefore
the data reported here are not necessarily representative of
European or national practices, as there may have been bias in
the type of centres participating. It is, however, worth pointing
out that a high proportion of patients enrolled into the ENACT
study were recruited in community hospitals and in institu-
tions without an on-site catheterisation laboratory.
Secondly, the data were provided by the participating
centres and therefore there may have been some over declara-
tion of secondary prevention measures in certain types of
hospital.
Thirdly, our adjusted analyses rely on a relatively limited
number of patient and hospital characteristics collected
within the scope of ENACT and should be interpreted with
caution, as a residual confounding effect from unmeasured
factors cannot be excluded.19
Finally, the treatments studied are by no means the only
effective methods of secondary prevention, and dietary advice,
smoking cessation, and other non-pharmacological and phar-
macological interventions to reduce weight, implement
exercise, and control other risk factors for coronary artery dis-
ease are also crucial to the ultimate prognosis of patients with
acute coronary syndromes. However, the treatments examined
have been proved clearly effective, and indeed their prescrip-
tion represents processes of care directly and sensitively linked
to outcome.20 21 Non-pharmacological secondary prevention
measures (for example, dietary advice and advice on smoking
cessation) are very important and their implementation was
not assessed in ENACT. However, it is likely that non-
pharmacological measures tend to “track” the prescription of
drugs for secondary prevention. In addition, only a minority of
patients treated for raised cholesterol in secondary prevention
achieve target concentrations,22 and the use of pharmacologi-
cal agents to lower cholesterol is a predictor of success in
achieving target concentrations of cholesterol.22
Table 5 Multivariate analysis of predictors of
prescription of lipid lowering agents at time of
discharge
Variable Wald χ2 OR 95% CI p Value
Dyslipidaemia 334.4 6.43 5.27 to 7.86 0.0001
Final diagnosis of
ACS
18.0 2.39 1.61 to 3.60 0.0001
PCI 13.9 1.48 1.20 to 1.83 0.0002
Reperfusion
treatment
13.5 1.44 1.18 to 1.75 0.0002
Age <70 years 46.3 1.89 1.57 to 2.25 0.0001
Hospital with
catheter lab
6.1 1.25 1.05 to 1.48 0.014
Hypertension 5.1 1.22 1.03 to 1.45 0.02
ACS, acute coronary syndrome; PCI, percutaneous coronary
intervention.
Table 6 In-hospital prescription rates of β blockers and ACE inhibitors
Variable






<12 h Other ACS
According to hospital type
Teaching hospital 68 66 57 47
Community hospital 71 64 55 45
According to availability of catheterisation facilities
With catheter lab 71 68* 54 43*
Without catheter lab 68 63 57 47
According to performance of procedures
Underwent angiography 70 77† 61 43
Underwent PCI 67 78† 62 43
Underwent neither 69 57 54 46
Values are %. *p<0.05 v hospitals without catheter lab; †p<0.05 v neither.
ACE, angiotensin converting enzyme; ACS, acute coronary syndrome; MI, myocardial infarction; PCI,
percutaneous coronary intervention.
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Conclusions
In this analysis of the ENACT registry, it appears that invasive
procedures for acute coronary syndromes are associated with
higher rates of prescription of aspirin and lipid lowering
agents at discharge, both in patients with myocardial
infarction associated with ST elevation and in patients with
other acute coronary syndromes. Performance of PCI is an
independent predictor of prescription of aspirin or lipid
lowering agents. In addition, admission to hospitals with
catheterisation laboratories was associated with a higher rate
of prescription of lipid lowering agents. These data suggest
that the current trend towards increased use of invasive
procedures is not responsible for the insufficient rates of pre-
scription of secondary prevention agents.
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Multiple ischaemic events set the pattern in patent foramen ovale
In cryptogenic stroke and patent foramen ovale (PFO) multiple ischaemic strokes or transient ischae-mic attacks (TIA) before diagnosis predispose to recurrent strokes later, Nedeltchev et al have found.Whether PFO causes cryptogenic stroke—through embolism of a venous clot across the atrial right to
left shunt—is debatable, though meta-analysis suggests that it does. Also, in the absence of controlled
trials there is no consensus about which patients with PFO are at risk of stroke, how many recurrences
they might have, and suitable treatment.
Nedeltchev et al believe that careful observational studies might help to answer these questions and
followed up 159 patients with cryptogenic stroke and PFO opting for medical treatment—oral
anticoagulants (79) or platelet inhibitors (80).
In three quarters of the patients the event leading to diagnosis of PFO was an ischaemic stroke; the rest
were TIA (24%) and amaurosis fugax (1%). The average annual rate of recurrent strokes and recurrent
strokes or TIAs measured over a mean of 29 months rose—from 1.8% to 3.6% and 5.5% to 9.9%,
respectively—when patients with multiple ischaemic events before diagnosis of PFO were analysed sepa-
rately. A log rank test on survival data confirmed that patients with multiple events were significantly
more at risk of later recurrences than those whose first event prompted the diagnosis. Recurrence rates
were comparable to those of previous studies, but neither treatment seemed better than the other.
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